World Library  
Flag as Inappropriate
Email this Article

Chemotherapy

Article Id: WHEBN0000007172
Reproduction Date:

Title: Chemotherapy  
Author: World Heritage Encyclopedia
Language: English
Subject: Oncology, Hair loss, Adjuvant therapy, Leukemia, Prostate cancer
Collection: Antineoplastic Drugs, Cancer Treatments, Chemotherapy, Oncology
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Chemotherapy

v/pmc/articles/PMC3658440" class="external text" rel="nofollow">"Nedaplatin: a cisplatin derivative in cancer chemotherapy". Cancer management and research 5: 67–76.  
  • ^ Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM; Estey; Appelbaum; Lo-Coco; Schiffer; Larson; Burnett; Kantarjian (17 September 2012). "Gemtuzumab Ozogamicin: Time to Resurrect?" (PDF). Journal of Clinical Oncology 30 (32): 3921–3923.  
  • ^ Lehnert M, Ludwig H, Zojer N; Ludwig; Zojer (February 2009). "Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma". OncoTargets and therapy 2: 199–208.  
  • ^ Cheson BD (2005). "The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.". BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 19 (5): 309–22.  
  • ^ Nabhan C, Kay NE; Kay; Chadi Nabhan (March 2011). "The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia". Clinical Medicine Insights. Oncology 5: 45–53.  
  • ^ Osterborg A (March 2010). "Ofatumumab, a human anti-CD20 monoclonal antibody.". Expert Opinion on Biological Therapy 10 (3): 439–49.  
  • ^ Sanford M, McCormack PL; McCormack (May 2010). "Ofatumumab". Drugs 70 (8): 1013–1019.  
  • ^ Davies AJ (28 May 2007). "Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab". Oncogene 26 (25): 3614–3628.  
  • ^ "Bexxar (tositumomab) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Gilotrif (afatinib)". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Zaltrap (ziv-aflibercept) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Escudier B, Gore M; Gore (2011). "Axitinib for the management of metastatic renal cell carcinoma". Drugs in R&D 11 (2): 113–26.  
  • ^ "Bosulif (bosutinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Amsberg GK, Koschmieder S; Koschmieder (March 2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia". OncoTargets and Therapy 6: 99–106.  
  • ^ "Xalkori (crizotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Forde PM, Rudin CM; Rudin (June 2012). "Crizotinib in the treatment of non-small-cell lung cancer". Expert opinion on pharmacotherapy 13 (8): 1195–201.  
  • ^ Frampton JE (28 November 2013). "Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer". Drugs 73 (18): 2031–2051.  
  • ^ Rothschild, SI; Gautschi, O (September 2013). "Crizotinib in the Treatment of Non–Small-Cell Lung Cancer". Clinical Lung Cancer 14 (5): 473–480.  
  • ^ Roskoski R (September 2013). "The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders". Expert Opinion on Drug Discovery 8 (9): 1165–1179.  
  • ^ "Iclusig (ponatinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Price KE, Saleem N, Lee G, Steinberg M; Saleem; Lee; Steinberg (August 2013). "Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia". OncoTargets and therapy 6: 1111–8.  
  • ^ "Stivarga (regorafenib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Strumberg D, Schultheis B; Schultheis (June 2012). "Regorafenib for cancer". Expert Opinion on Investigational Drugs 21 (6): 879–889.  
  • ^ Aprile G, Macerelli M, Giuliani F; MacErelli; Giuliani (23 February 2013). "Regorafenib for Gastrointestinal Malignancies". BioDrugs 27 (3): 213–224.  
  • ^ Shahda S, Saif MW; Saif (May 2013). "Regorafenib: from bench to bedside in colorectal cancer". Expert Review of Clinical Pharmacology 6 (3): 243–248.  
  • ^ "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ "JAKAVI® Ruxolitinib" (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Limited. 21 January 2014. 
  • ^ Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN; Silver; Komrokji; Mesa; Tacke; Harrison (December 2013). "Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects" (PDF). Clinical Lymphoma Myeloma and Leukemia 13 (6): 638–645.  
  • ^ Vaddi K, Sarlis NJ, Gupta V; Sarlis; Gupta (November 2012). "Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis". Expert Opinion on Pharmacotherapy 13 (16): 2397–2407.  
  • ^ "Vandetanib dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Targretin (bexarotene) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Matthay KK (3 December 2012). "Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption". Clinical Cancer Research 19 (2): 311–313.  
  • ^ "Amnesteem, Claravis (isotretinoin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Isotretinoin 20mg capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Alliance Pharmaceuticals. 12 April 2013. Retrieved 9 February 2014. 
  • ^ Miwako I, Kagechika H; Kagechika (August 2007). "Tamibarotene". Drugs of today (Barcelona, Spain: 1998) 43 (8): 563–8.  
  • ^ Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K; Nakagomi; Yamagata; Katsuki; Kawahara; Kitaoka; Miki; Shudo (2012). "Tamibarotene: a candidate retinoid drug for Alzheimer's disease". Biological & Pharmaceutical Bulletin 35 (8): 1206–12.  
  • ^ Takeuchi M (March 2006). "[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].". Gan to kagaku ryoho. Cancer & chemotherapy (in Japanese) 33 (3): 397–401.  
  • ^ "Istodax (romidepsin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ Bellos F, Mahlknecht U; Mahlknecht (November 2008). "Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients". Onkologie 31 (11): 629–33.  
  • ^ Blaheta RA, Nau H, Michaelis M, Cinatl J; Nau; Michaelis; Cinatl Jr (August 2002). "Valproate and valproate-analogues: potent tools to fight against cancer". Current medicinal chemistry 9 (15): 1417–33.  
  • ^ Blaheta RA, Cinatl J; Cinatl Jr (September 2002). "Anti-tumor mechanisms of valproate: a novel role for an old drug". Medicinal Research Reviews 22 (5): 492–511.  
  • ^ Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA; Candelaria; Perez-Plascencia; Perez-Cardenas; de la Cruz-Hernandez; Herrera (May 2008). "Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors". Cancer treatment reviews 34 (3): 206–22.  
  • ^ "Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ "Ontak (denileukin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Lansigan F, Stearns DM, Foss F; Stearns; Foss (February 2010). "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma". Cancer Management and Research 2: 53–59.  
  • ^ Manoukian G, Hagemeister F; Hagemeister (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy 9 (11): 1445–1451.  
  • ^ Kaminetzky D, Hymes KB; Hymes (December 2008). "Denileukin diftitox for the treatment of cutaneous T-cell lymphoma". Biologics: Targets & Therapy 2 (4): 717–724.  
  • ^ Top 10 best-selling cancer drugs of 2013; May 29, 2014
  • Bibliography

    • Rachel Airley (2009). Cancer chemotherapy. Wiley-Blackwell.  
    • Wood, Miriam; David Brighton (2005). The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team. St. Louis, Mo: Elsevier Churchill Livingstone.  
    • Fergus Macbeth; Hanna, Louise; Crosby, Tom (2008). Practical clinical oncology. Cambridge, UK: Cambridge University Press. 
    • Perry, Michael J. (2008). The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 
    • Faguet, Guy B. (2005). The War on Cancer. Springer. p. 71.  
    • Hirsch J (September 2006). "An anniversary for cancer chemotherapy". JAMA 296 (12): 1518–20.  
    • Huang, Elbert S. (2000). Internal medicine: handbook for clinicians, resident survival guide. Arlington, VA: Scrub Hill Press. p. 130.  
    • Randall, [edited by] William J. Hoskins, Carlos A. Perez, Robert C. Young, Richard R. Barakat, Maurie Markman, Marcus E. (2005). Principles and practice of gynecologic oncology (4. ed.). Baltimore, Md.: Lippincott Williams & Wilkins. pp. 93–94.  

    External links

    • Search for chemotherapy trials
    • American Cancer Society - Chemotherapy
    • Chemotherapy side effects
    This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
     
    Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
     
    By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
     


    Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
    a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.